Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human dose-escalation and dose-expansion study of ODM-212 in advanced solid tumors with Hippo pathway alterations
ISRCTN99739590Phase 2Active, not recruiting
- Sponsor
- Orion Corporation
- Start
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of ODM-212 in Nonhematologic neoplasms (2 arms), sponsored by Orion Corporation. Primary endpoints: Treatment-emergent adverse events and General safety assessments. Started Oct 2023; status: active, not recruiting.
02
Drugs
ODM-212
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN99739590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99739590.